Abstract

Objectives

We report cancer incidence, mortality, and stage distributions among Asians and Pacific Islanders (API) residing in the U.S. and note health disparities, using the cancer experience of the non-Hispanic white population as the referent group. New databases added to publicly available SEER*Stat software will enable public health researchers to further investigate cancer patterns among API groups.

Methods

Cancer diagnoses among API groups occurring from 1 January 1998 to 31 December 2002 were included from 14 Surveillance, Epidemiology, and End Results (SEER) Program state and regional population-based cancer registries covering 54% of the U.S. API population. Cancer deaths were included from the seven states that report death information for detailed API groups and which cover over 68% of the total U.S. API population. Using detailed racial/ethnic population data from the 2000 decennial census, we produced incidence rates centered on the census year for Asian Indians/Pakistanis, Chinese, Filipinos, Guamanians, Native Hawaiians, Japanese, Kampucheans, Koreans, Laotians, Samoans, Tongans, and Vietnamese. State vital records offices do not report API deaths separately for Kampucheans, Laotians, Pakistanis, and Tongans, so mortality rates were analyzed only for the remaining API groups.

Results

Overall cancer incidence rates for the API groups tended be lower than overall rates for non-Hispanic whites, with the exception of Native Hawaiian women (All cancers rate = 488.5 per 100,000 vs. 448.5 for non-Hispanic white women). Among the API groups, overall cancer incidence and death rates were highest for Native Hawaiian and Samoan men and women due to high rates for cancers of the prostate, lung, and colorectum among Native Hawaiian men; cancers of the prostate, lung, liver, and stomach among Samoan men; and cancers of the breast and lung among Native Hawaiian and Samoan women. Incidence and death rates for cancers of the liver, stomach, and nasopharynx were notably high in several of the API groups and exceeded rates generally seen for non-Hispanic white men and women. Incidence rates were lowest among Asian Indian/Pakistani and Guamanian men and women and Kampuchean women. Asian Indian and Guamanian men and women also had the lowest cancer death rates. Selected API groups had less favorable distributions of stage at diagnosis for certain cancers than non-Hispanic whites.

Conclusions

Possible disparities in cancer incidence or mortality between specific API groups in our study and non-Hispanic whites (referent group) were identified for several cancers. Unfavorable patterns of stage at diagnosis for cancers of the colon and rectum, breast, cervix uteri, and prostate suggest a need for cancer control interventions in selected groups. The observed variation in cancer patterns among API groups indicates the importance of monitoring these groups separately, as these patterns may provide etiologic clues that could be investigated by analytic epidemiological studies.

Key words

Cancer Incidence Mortality Race Ethnicity Asian Pacific Islander SEER Program

Introduction

A goal of the U.S. Department of Health and Human Service’s Healthy People 2010 program is the elimination of health disparities that occur by race and ethnicity [1]. Health disparities have been defined as “…differences in the incidence, prevalence, mortality, and burden of diseases and other adverse health conditions that exist among specific population groups in the United States [2].” This definition implies that a cancer health disparity exists when one segment of a population is found to have higher cancer rates (or some other measure of interest that indicates adverse conditions) than another population segment, or referent group. In this study, we report cancer incidence, mortality, and stage distributions among Asians and Pacific Islanders (API) residing in the U.S. and note health disparities, using the cancer experience of the non-Hispanic white population as the referent group. We identify specific API groups that may benefit from cancer control interventions or from further analytic epidemiologic research to follow up on etiologic leads.

Cancer surveillance systems, composed of high quality population-based (state or metropolitan area) central cancer registries, enable the monitoring of health disparities related to cancer incidence, mortality, patient survival, treatment, and quality of life [3]. The broad geographic coverage of national surveillance programs, such as the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program which currently includes 26% of the U.S. population, facilitates the inclusion of more detailed racial/ethnic groups in such analyses by virtue of the large population base. Similarly, data from several state vital records offices that collect and report death information for an expanded set of racial/ethnic groups enables the identification of disparities in cancer mortality [4]. The lack of comparably-detailed racial/ethnic population estimates, however, often constrains U.S. health surveillance systems to report cancer rates for combined groups, such as API. This limitation obscures important differences in the cancer experience of heterogeneous populations [57]. As a result, national statistics on cancer for Asian ethnic groups are not routinely available [8]. In this study, we have taken advantage of population data from the 2000 decennial census for detailed racial/ethnic groups, to calculate incidence and mortality rates for several specific API groups: Asian Indian/Pakistani, Chinese, Filipino, Guamanian, Native Hawaiian, Japanese, Kampuchean, Korean, Laotian, Samoan, Tongan, and Vietnamese (mortality data only are available for a subset of these groups—see Materials and methods). The databases used in these analyses can be accessed, under a data user agreement, from the SEER Web site [9].

Material and methods

Study data

Information on new cancer diagnoses among API groups and non-Hispanic whites (referent group) occurring during the 5-year period from 1 January 1998 to 31 December 2002 was obtained from U.S. state and regional population-based cancer registries that participate in the NCI’s SEER Program. The reporting areas included in this analysis were: Atlanta, Detroit, Seattle/Puget Sound; and the states of California (registries for Los Angeles County, the Greater San Francisco Bay Area, and the rest of California), Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah. These registries cover 54% of the U.S. API population [10]. The specific API groups included in the incidence comparisons were Asian Indian/Pakistani (combined, due to SEER coding rules [11]), Chinese, Filipino, Guamanian, Native Hawaiian, Japanese, Kampuchean, Korean, Laotian, Samoan, Tongan, and Vietnamese. Approximately 7% of the API cancer cases were classified as “Asian not otherwise specified” (NOS) or “Pacific Islander NOS” and could not be included in the analysis. Only invasive cancers were analyzed, with the exception of the urinary bladder. Bladder cancers reported as either in situ or invasive were combined, since information in medical records needed to distinguish between these types of tumors is frequently either unavailable or unreliable [12]. The primary cancer type was coded according to the International Classification of Diseases for Oncology (ICD-O) edition in use at the time of diagnosis, converted to ICD-O Third Edition, and then categorized into cancer site groupings [13].

Cancer deaths occurring during the 1998–2002 study period were identified from all deaths reported to state vital records offices and consolidated by the National Vital Statistics System of the National Center for Health Statistics. The underlying cause of death was coded based on the version of the International Classification of Diseases (ICD) in use at the time of death. Deaths due to malignant neoplasm were then grouped to ensure comparability of disease categories across the ICD versions [13]. Since specification of expanded API racial categories on death certificates is currently required for seven states only (California, Hawaii, Illinois, New Jersey, New York, Texas, and Washington) and for nine API ethnic groups [14], we restricted our mortality analyses to these areas and groups (Table 1). Thus, the geographic coverage differs between the incidence and mortality analyses. Approximately 72% of the API population covered in the mortality analysis is also included in the incidence analysis. The seven states in the mortality analysis include over 68% of the total U.S. API population; representing 80% of Native Hawaiians, 79% of Filipinos, 77% of Japanese, 74% of Chinese and of Samoans, 65% of Koreans, 62% of Vietnamese, 61% of Guamanians, and 60% of Asian Indians [15]. Less than 0.1% of the API deaths were classified as “API NOS” and were excluded from the analysis. Deaths among non-Hispanic whites in these states are also included for purposes of comparison.
Table 1

Geographic areas included in cancer incidence and mortality rates for each racial/ethnic group, 1998–2002

 

Incidence rates

Mortality rates

CAa

CT

HI

IA

KY

LA

NJ

NM

UT

Atlanta metro

Detroit metro

Seattle–Puget Soundb

CA, HI, IL, NJ, NY, TX, and WA

Asian Indian or Pakistanic

X

X

d

X

X

X

X

X

X

X

X

2

X

Chinese

X

X

X

X

X

X

X

X

X

X

X

9

X

Filipino

X

X

X

X

X

X

X

X

X

X

X

11

X

Guamanian

X

e

X

e

e

e

e

e

e

d

d

6

X

Native Hawaiian

  

Xf

         

Xf

Japanese

X

X

X

X

X

X

X

X

X

X

X

9

X

Kampuchean

X

X

e

e

e

e

e

d

X

X

d

6

g

Korean

X

X

X

X

X

X

X

X

X

X

X

10

X

Laotian

X

X

X

X

e

X

e

e

X

X

X

4

g

Samoan

X

e

X

e

e

e

e

e

X

d

d

5

X

Tongan

X

d

X

d

d

d

d

d

X

d

d

1e

g

Vietnamese

X

X

X

X

X

X

X

X

X

X

X

6

X

X—Indicates area was included in rate calculations

aIncludes cancer registries for Los Angeles, San Francisco/Oakland, San Jose/Monterey, and all remaining areas in California combined

bIndicates number of counties within the 11-county Seattle–Puget Sound area for which population estimates were NOT suppressed by the Census Bureau; and thus could be included in the incidence analyses

cIncidence rates calculated for combined group of Asian Indians & Pakistanis due to SEER program coding rules; mortality rates calculated only for Asian Indians due to NCHS coding rules

dArea not included in rate calculation due to supression of population data by Census Bureau

eArea not included in rate calculation due to small population size (<1,000); see materials and methods and Statistical analysis

fNative Hawaiian rates calculated only for the state of Hawaii

gMortality data not available from NCHS for these race/ethnic groups [3]

Data analysis

Cancer incidence and mortality rates were calculated for the combined 5-year study period, 1998–2002, as cases or deaths per 100,000 persons. The rates were age-adjusted to the 2000 U.S. standard population using 19 age groups (<1, 1–4, 5–9,…, 80–84, 85+). Rates and 95% confidence intervals (95% CI) [16] were generated using SEER*Stat software [http://www.seer.cancer.gov/seerstat/]. As rates based on small counts (either the number of diagnosed cases or deaths) tend to have poor reliability, they are not shown in tables if the case or death count is  <16 [17, 18].

Detailed population data for specific API groups are available only from the decennial U.S. census. Therefore, we centered our study on the 2000 census and used the population counts, multiplied by five, as denominators for incidence and mortality rate calculations. In the 2000 census, individuals were able to indicate multiple race/ethnic responses on the census form [19]. These responses can be tabulated as two population values for detailed API groups; namely, the specific API group alone (counting those who self-identified with only one API group) and the specific API group alone or in combination with any other racial/ethnic groups (counting those who self-identified with either a single API group or with more than one racial/ethnic group, at least one of which was the specific API group of interest). Thus, the population counts for each of the specific API groups are not mutually exclusive. Population data for non-Hispanic whites consist of bridged single-race estimates available for each year from 1998 to 2002 [20, 21].

Cancer registries and state vital records offices have also begun collecting and reporting multiple race and ethnicity information from medical records and death certificates. These sources, however, generally include only a single race or ethnicity designation (>99.95% of cancer diagnoses in SEER registries, data not shown). Therefore, only single race or ethnicity information was used for classifying cases and deaths in this study [11, 22].

Due to the lack of consistency between racial/ethnic information for the numerators (generally, single race from medical records or state vital records offices) and population denominators (either self-reported single race alone; or single race alone or in combination with other races), we calculated two rates for each cancer type, specific API group, and gender. These may be considered as representing a maximum rate (based on the smaller, single-race/ethnicity alone denominator) [23] and a minimum rate (based on the larger denominator that includes both multiple-race/ethnicity and single-race/ethnicity respondents) [24].

Census Bureau policy for Census 2000 data is to not disclose race/ethnicity-specific population counts below 100 for a particular geographic area [25]. Thus, we were unable to obtain comprehensive population denominators for some of the SEER reporting areas. When race/ethnicity-specific census population data were suppressed for an entire registry, the registry was excluded from rate calculations for that particular API group. However, when the census population data were suppressed for a subset of the counties within the Seattle/Puget Sound metropolitan area, we chose to calculate an incidence rate that included all remaining counties for which the race/ethnic-specific population data were not suppressed. This resulted in the exclusion of selected counties in Seattle/Puget Sound from incidence rate calculations for each of the API groups, with the exception of Filipinos (Table 1).

In addition, when a specific API population group in a SEER registry coverage area was less than 1,000 (based on single race/ethnicity alone population data), the data for that area was excluded from the cancer incidence rate calculations for that group. The rationale for this exclusion was that incidence rates for specific API groups in these registries with small populations were generally low; suggesting that misclassification of API ethnic information in medical records may be a bigger problem in these areas. Using this population threshold limited the number of geographic areas for Guamanians, Kampucheans, Laotians, Samoans, and Tongans (Table 1), but excluded just 1–2% of the total number of cancer cases in these groups. Cancer incidence and mortality rates for Native Hawaiians are reported only for the State of Hawaii due to the extensive efforts at the Hawaii Tumor Registry to classify all cancer patients with any native Hawaiian ancestry and because of the unique cultural and environmental characteristics of this group [26]. About 60% of the total U.S. Native Hawaiian population resides in Hawaii.

We examined the distribution of stage of disease at diagnosis for cancers of the colon and rectum, female breast, cervix uteri, and prostate using the SEER historical stage categories of localized, regional, and distant disease [27]. Due to changing medical practices in characterizing prostate cancers, we combined localized and regional prostate cancer cases for the analysis by stage. The age-adjusted distribution of stage at diagnosis for selected cancers was calculated in the following manner. An age-adjusted incidence rate was computed using the direct method for each particular stage group for a specific cancer site, it was then divided by the age-adjusted incidence rate for all stages combined, and the resulting proportion was converted to a percentage.

Results

To simplify the presentation of our findings, incidence, and mortality rates appearing in the tables are limited to those based on the single race/ethnicity denominators, with the exception of Native Hawaiian rates. Since the Hawaii Tumor Registry collects extensive multiple race/ethnicity information on their cancer patients and classifies a patient with any native Hawaiian ancestry as native Hawaiian, the most appropriate population denominator for a native Hawaiian rate is the one that includes Hawaiian alone or in any combination. Regardless of which denominators were used, the relative rankings of the cancer sites remained the same for all API groups, however, the magnitude of all the rates were reduced when larger denominators (i.e., population counts based on the specific API group alone or in combination with other any other racial/ethnic group), were used. Rates based on both single race/ethnicity and one or more race/ethnicity denominators are included as appendices. The appendices also include case counts and 95% CI for the rates.

Incidence rates: Men

The overall cancer incidence rates were highest among Native Hawaiian and Samoan men, due to high rates of prostate and lung cancers (Table 2), but they do not exceed the overall cancer rate for non-Hispanic white men (Table 4). Lung cancer incidence in Native Hawaiian men, however, was higher than that for non-Hispanic white men. Asian Indian/Pakistani and Guamanian men had the lowest overall cancer rates among the API groups, and Asian Indians/Pakistanis had relatively low rates for lung and colorectal cancers. Prostate cancer was the leading cancer in Asian Indian/Pakistani, Chinese, Filipino, Guamanian, Native Hawaiian, Japanese, and Samoan men, while lung cancer rates were highest in Kampuchean, Korean, Laotian, Tongan, and Vietnamese men. Colorectal cancer was among the top three cancers in Asian Indian/Pakistani, Chinese, Filipino, Native Hawaiian, Japanese, Korean, and men; whereas liver cancer was among the top three in Kampuchean, Laotian, Samoan, and Vietnamese men. Japanese men had the highest colorectal cancer rate (75.9 per 100,000; 95% CI: 71.9, 80.2) and this exceeded the rate in non-Hispanic white men. Among Laotian men, incidence rates for lung, liver, and stomach cancers all exceeded the rate for prostate cancer; in fact, their prostate cancer rate (30.9; 95% CI: 18.2, 51.9) was lowest among the API groups in our study. Stomach cancer was among the top five cancers in all API groups, with the exception of Asian Indian/Pakistani and Filipino men, but ranked much lower in non-Hispanic white men (Appendix Table 1). Rates of stomach cancer were particularly high for Korean (50.0; 95% CI: 44.6, 56.2) and Samoan men (53.0; 95% CI: 33.2, 86.1). Liver cancer was also among the top five cancers in Chinese, Filipino, Kampuchean, Korean, Laotian, Samoan, and Vietnamese men. The liver cancer rate was highest in Laotian men (79.4; 95% CI: 60.7, 105.0). Rates for nasopharyngeal cancer were highest in Chinese and Vietnamese men, but not among the top five cancers for any group, and greatly exceeded the rate in non-Hispanic white men (Appendix Table 1). Nasopharyngeal cancer may also have been high in other API groups, but the number of cases in our study were too small to produce reliable rates.
Table 2

Top five age-adjusted cancer incidence ratesa and 95% CI by Asian or Pacific Islander subgroup, 1998–2002: Men

Rank

 

Asian Indian or Pakistani

Chinese

Filipino

 

Rate

(95% CI)

 

Rate

(95% CI)

 

Rate

(95% CI)

 

All cancers

292.1

(277.3, 307.9)

All cancers

348.8

(341.5, 356.2)

All cancers

393.2

(385.0, 401.5)

1

Prostate

98.4

(90.0, 107.7)

Prostate

84.8

(81.2, 88.5)

Prostate

121.9

(117.3, 126.6)

2

Lung

30.8

(25.7, 36.8)

Colorectum

54.0

(51.2, 57.0)

Lung

72.5

(69.0, 76.1)

3

Colorectum

23.1

(19.3, 27.9)

Lung

53.0

(50.1, 56.0)

Colorectum

50.4

(47.5, 53.4)

4

Non-Hodgn

15.8

(12.5, 20.1)

Liver

24.0

(22.1, 25.9)

Non-Hodgn

19.4

(17.7, 21.4)

5

Bladder

15.8

(12.1, 20.5)

Stomach

18.3

(16.6, 20.2)

Liver

17.2

(15.5, 19.0)

 

Guamanian

Native Hawaiianb

Japanese

 

All cancers

252.1

(189.8, 336.7)

All cancers

531.6

(503.7, 561.1)

All Cancers

422.4

(412.8, 432.3)

1

Prostate

131.5

(85.0, 202.4)

Prostate

119.7

(106.1, 135.1)

Prostate

115.0

(110.1, 120.1)

2

nr

  

Lung

109.8

(97.4, 123.9)

Colorectal

75.9

(71.9, 80.2)

3

nr

  

Colorectal

65.7

(56.1, 77.1)

Lung

49.8

(46.6, 53.3)

4

nr

  

Bladder

21.2

(15.3, 29.1)

Stomach

29.3

(26.9, 32.1)

5

nr

  

Non-Hodgn

19.6

(14.8, 26.3)

Bladder

22.9

(20.8, 25.4)

 

Kampuchean

Korean

Laotian

 

All cancers

372.0

(325.3, 425.5)

All cancers

372.6

(357.4, 388.4)

All Cancers

407.2

(360.7, 460.3)

1

Lung

82.6

(60.1, 112.6)

Lung

61.1

(54.8, 68.2)

Lung

87.3

(64.9, 117.4)

2

Liver

49.1

(36.3, 68.5)

Colorectum

55.9

(50.2, 62.2)

Liver

79.4

(60.7, 105.0)

3

Prostate

39.7

(25.0, 62.2)

Prostate

55.7

(49.8, 62.3)

Stomach

33.1

(19.1, 55.8)

4

Colorectum

30.0

(18.3, 49.5)

Stomach

55.0

(44.6, 56.2)

Prostate

30.9

(18.2, 51.9)

5

Stomach

23.8

(12.1, 44.3)

Liver

35.9

(31.6, 40.8)

Colorectum

30.2

(19.4, 48.8)

 

Samoan

Tongan

Vietnamese

 

All cancers

566.7

(498.8, 645.5)

All cancers

428.8

(329.9, 555.9)

All Cancers

374.3

(358.5, 390.9)

1

Prostate

144.1

(110.0, 190.4)

Lung

107.0

(55.2, 193.0)

Lung

72.3

(65.3, 80.2)

2

Lung

111.9

(84.4, 151.1)

Prostate

85.0

(44.5, 157.4)

Prostate

59.1

(52.8, 66.3)

3

Liver

54.5

(35.2, 86.9)

nr

  

Liver

55.5

(49.9, 62.0)

4

Stomach

53.0

(33.2, 86.1)

nr

  

Colorectum

41.2

(36.1, 47.1)

5

Colorectum

43.1

(26.6, 72.8)

nr

  

Stomach

25.6

(21.2, 30.9)

aRates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following SEER areas: Atlanta, Detroit, Seattle/Puget Sound; and the states of California (registries for Los Angeles County, the Greater San Francisco Bay Area, and the rest of California), Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah

bRates for Native Hawaiians are calculated using the one or more race/ethnicities population denominators for Hawaii only (See Materials and methods)

Abbreviations: Lung = lung and bronchus; Liver = liver and intrahepatic bile duct; Non-Hodgn = non-Hodgkin lymphoma

Incidence rates: Women

Native Hawaiian, Samoan, and Tongan women had the highest overall cancer incidence rates, while Asian Indian/Pakistani, Guamanian, and Kampuchean women had the lowest rates (Table 3). The cancer rate in Native Hawaiian women even exceeds that of non-Hispanic white women (Table 4). Breast cancer was the leading cancer in each female API group with the exception of Laotian women, for whom lung cancer had the highest age-adjusted incidence rate and breast cancer had the second highest rate, though the variability associated with each of these rates was large. Breast cancer incidence was highest among Native Hawaiian women (175.8; 95% CI: 163.0, 189.4) and exceeded the rate in non-Hispanic white women. Lung cancer was among the top four cancers in every female API group and Native Hawaiian women had the highest rate (69.7; 95% CI: 61.2, 79.1). Colorectal cancer was one of the top four cancers in all groups for whom there were sufficient data. Japanese women, similar to the men, had the highest colorectal cancer rate (51.9; 95% CI: 49.1, 55.0) among the racial/ethnic groups, even exceeding the rate in non-Hispanic white women. Cervical cancer was among the top five cancers in Kampuchean, Laotian, Samoan, and Vietnamese women and their rates exceeded that for non-Hispanic white women (Appendix Table 1). Endometrial cancer was among the top four leading cancers for all groups with the exception of Kampuchean, Korean, Laotian, and Vietnamese women. Liver cancer was the fifth leading cancer in Kampuchean, Korean, Laotian, and Vietnamese women. Stomach cancer was among the top five cancers for Chinese, Japanese, and Korean women, and greatly exceeded the rate in non-Hispanic white women. As observed in men, nasopharyngeal cancer rates were highest in Chinese and Vietnamese women, while small numbers of cases precluded an evaluation of the rates in many of the other API groups (Appendix Table 1).
Table 3

Top five age-adjusted cancer incidence ratesa and 95% CI by Asian or Pacific Islander subgroup, 1998–2002: Women

Rank

 

Asian Indian or Pakistani

Chinese

Filipina

 

Rate

(95% CI)

 

Rate

(95% CI)

 

Rate

(95% CI)

 

All cancers

238.1

(226.7, 250.2)

All cancers

270.4

(264.7, 276.2)

All cancers

291.1

(285.3, 297.1)

1

Breast

82.1

(76.1, 88.8)

Breast

77.6

(74.6, 80.6)

Breast

100.4

(97.1, 103.8)

2

Colorectum

18.8

(15.5, 23.0)

Colorectum

40.2

(38.0, 42.5)

Colorectum

29.4

(27.5, 31.4)

3

Endometrium

13.5

(10.9, 16.7)

Lung

29.7

(27.8, 31.7)

Lung

26.0

(24.1, 27.9)

4

Lung

13.1

(10.2, 16.9)

Endometrium

12.0

(10.9, 13.3)

Endometrium

18.6

(17.2, 20.1)

5

Ovary

12.0

(9.7, 15.1)

Stomach

11.1

(10.0, 12.4)

Thyroid

17.7

(16.4, 19.2)

 

Guamanian

Native Hawaiianb

Japanese

 

All cancers

175.6

(132.7, 233.8)

All cancers

488.5

(466.5, 511.3)

All Cancers

342.4

(334.5, 350.2)

1

Breast

45.0

(28.3, 78.1)

Breast

175.8

(163.0, 189.4)

Breast

126.5

(121.7, 131.5)

2

Lung

40.7

(22.4, 76.4)

Lung

69.7

(61.2, 79.1)

Colorectum

51.9

(49.1, 55.0)

3

nr

  

Colorectum

44.0

(37.3, 51.6)

Lung

24.7

(22.8, 26.8)

4

nr

  

Endometrium

37.5

(31.9, 44.1)

Endometrium

20.4

(18.5, 22.6)

5

nr

  

Pancreas

18.6

(14.3, 23.9)

Stomach

15.0

(13.6, 16.8)

 

Kampuchean

Korean

Laotian

 

All cancers

212.3

(185.9, 242.4)

All cancers

254.5

(245.2, 264.1)

All Cancers

297.9

(263.0, 337.1)

1

Breast

38.2

(28.3, 51.8)

Breast

53.5

(49.7, 57.6)

Lung

44.4

(31.2, 62.3)

2

Lung

24.6

(15.6, 37.8)

Colorectum

35.9

(32.3, 39.8)

Breast

36.9

(26.5, 51.5)

3

Colorectum

21.1

(13.1, 33.2)

Lung

27.5

(24.3, 31.0)

Colorectum

27.5

(17.1, 42.7)

4

Cervix Uteri

15.3

(9.3, 25.3)

Stomach

26.3

(23.3, 29.7)

Cervix Uteri

24.8

(16.0, 38.0)

5

Liver

14.1

(7.6, 24.9)

Liver

14.4

(12.2, 17.0)

Liver

23.1

(14.5, 36.4)

 

Samoan

Tongan

Vietnamese

 

All cancers

472.0

(421.5, 528.6)

All cancers

504.7

(414.1, 616.6)

All Cancers

270.6

(259.6, 282.2)

1

Breast

102.5

(81.7, 129.5)

Breast

118.0

(78.1, 181.2)

Breast

52.8

(48.6, 57.5)

2

Endometrium

66.1

(50.3, 88.2)

Endometrium

91.2

(56.4, 150.1)

Lung

34.4

(30.3, 39.1)

3

Lung

56.9

(39.6, 81.3)

nr

  

Colorectum

33.3

(29.3, 37.8)

4

Colorectum

38.6

(24.1, 60.5)

nr

  

Cervix Uteri

16.8

(14.3, 19.8)

5

Cervix Uteri

18.1

(10.6, 32.7)

nr

  

Liver

16.8

(14.0, 20.1)

aRates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following SEER areas: Atlanta, Detroit, Seattle/Puget Sound; and the states of California (registries for Los Angeles County, the Greater San Francisco Bay Area, and the rest of California), Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah

bRates for Native Hawaiians are calculated using the one or more race/ethnicities population denominators for Hawaii only (See Materials and methods)

Abbreviations: Lung = lung and bronchus; Liver = liver and intrahepatic bile duct; Endometrium = corpus uterus, NOS

Stage distribution

Age-adjusted percentage stage distributions are shown for cancers of the colon and rectum, female breast, cervix uteri, and prostate in Figs. 1a–d, 1e. Laotian, Samoan, and Vietnamese men had lower percentages of colorectal cancers diagnosed at an early (localized) stage relative to the other API groups and to non-Hispanic whites. The total number of cases was fairly small, however, for Laotian (n = 30) and Samoan (n = 31) men. Among women, Laotians again had a lower percentage of localized stage diagnoses, but this was also based on a small total number of colorectal cancers (n = 24). For female breast cancer, Laotian, Samoan, and Tongan women had a smaller percentage of cases diagnosed at localized stage than the other groups. The total number of breast cancer cases in each of these groups was 45, 94, and 35, respectively. Kampuchean, Laotian, and Samoan women had smaller percentages of cervical cancers diagnosed at localized stage (total number of cervical cancers = 22, 28, and 19, respectively). Comparisons of the stage distribution of prostate cancer across the API groups indicated that Kampuchean, Samoan, and Tongan men had smaller percentages of local/regional cancers than the other groups, though the total number of cases was limited (n = 27, 77, and 16, respectively).
https://static-content.springer.com/image/art%3A10.1007%2Fs10552-007-9088-3/MediaObjects/10552_2007_9088_Fig1a-d_HTML.gif
https://static-content.springer.com/image/art%3A10.1007%2Fs10552-007-9088-3/MediaObjects/10552_2007_9088_Fig1e_HTML.gif
Fig. 1

(a) Age-adjusted percentage distributions of stage at diagnosis for colorectal cancer,1998–2002: Men. (b) Age-adjusted percentage distributions of stage at diagnosis for colorectal cancer, 1998–2002: Women. (c) Age-adjusted percentage distributions of stage at diagnosis for breast cancer, 1998–2002: Women. (d) Age-adjusted percentage distributions of stage at diagnosis for cervix uteri cancer, 1998–2002: Women. (e) Age-adjusted percentage distributions of stage at diagnosis for prostate cancer, 1998–2002: Men

Mortality rates: Men

The overall cancer death rates were highest among Samoan and Native Hawaiian men (Table 5) and, unlike the incidence rates, exceeded the overall cancer death rate for non-Hispanic white men (Table 4). Asian Indian men had the lowest overall cancer mortality rate among the API groups, largely due to relatively low rates for lung and colorectal cancers. Lung and bronchus cancer had the highest age-adjusted death rate for each Asian ethnic group. Native Hawaiian men had the highest lung cancer rate (87.7 per 100,000; 95% CI: 76.4, 100.7), and exceeded the rate in non-Hispanic white men (72.2 per 100,000; 95% CI: 71.8, 72.7). Prostate cancer mortality was among the top three causes of cancer death in Asian Indian, Filipino, Native Hawaiian, and Samoan men. Samoan men had the highest rate (36.2 per 100,000; 95% CI: 18.9, 64.4), but it is based on relatively few deaths and its confidence interval includes the rates seen for native Hawaiian and non-Hispanic white men. Colorectal cancer was among the top three causes of cancer death in Chinese, Filipino, Native Hawaiian, and Japanese men. Samoans had the highest rate (31.6 per 100,000; 95% CI: 17.2, 56.0). Liver cancer was in the top four causes of cancer death for all male Asian ethnic groups, except, Native Hawaiians and Japanese. Samoans also had the highest rate for this site (32.9 per 100,000; 95% CI: 19.3, 56.1). Stomach cancers were in the top four causes of cancer death for all male Asian ethnic groups, except Asian Indians and Filipinos. Samoans had the highest rate for this site as well (40.9 per 100,000; 95% CI: 24.1, 67.6).
Table 4

Top five age-adjusted cancer rates and 95% CI for non-Hispanic white men and women, 1998–2002

 

Rank

Men

Women

 

Rate

(95% CI)

 

Rate

(95% CI)

Incidence a

 

All cancers

587.0

(585.6, 588.5)

All cancers

448.5

(447.3, 449.6)

1

Prostate

170.0

(169.3, 170.8)

Breast

145.2

(144.5, 145.8)

2

Lung

89.2

(88.7, 89.8)

Lung

59.0

(58.6, 59.4)

3

Colorectum

65.6

(65.2, 66.1)

Colorectum

47.6

(47.2, 47.9)

4

Bladder

43.0

(42.6, 43.4)

Endometrium

26.0

(25.7, 26.2)

5

Melanoma

29.3

(29.0, 29.6)

Melanoma

19.3

(19.0, 19.5)

Mortality b

 

All cancers

241.3

(240.5, 242.1)

All cancers

171.7

(171.1, 172.2)

1

Lung

72.2

(71.8, 72.7)

Lung

44.5

(44.2, 44.8)

2

Prostate

27.7

(27.4, 28.0)

Breast

27.8

(27.5, 28.0)

3

Colorectum

24.6

(24.3, 24.8)

Colorectum

17.3

(17.1, 17.5)

4

Pancreas

12.6

(12.4, 12.8)

Ovary

9.8

(9.7, 9.9)

5

Non-Hodgkin

10.6

(10.5, 10.8)

Pancreas

9.5

(9.4, 9.6)

aRates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following SEER areas: Atlanta, Detroit, Seattle/Puget Sound; and the states of California (registries for Los Angeles County, the Greater San Francisco Bay Area, and the rest of California), Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah

bRates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following States: California, Hawaii, Illinois, New Jersey, New York, Texas, and Washington

Abbreviations: Lung = lung and bronchus; Endometrium = corpus uterus, NOS; Non-Hodgn = non-Hodgkin lymphoma

Table 5

Top five age-adjusted cancer mortality ratesa and 95% CI by Asian or Pacific Islander subgroup, 1998–2002: Men

Rank 

Korean

Samoan

Vietnamese

 

Rate

(95% CI)

 

Rate

(95% CI)

 

Rate

(95% CI)

 

All cancers

82.8

(75.7, 90.5)

All cancers

167.8

(163.4, 172.4)

All Cancers

155.6

(150.6, 160.8)

1

Lung

17.2

(14.1, 21.1)

Lung

47.0

(44.78, 49.5)

Lung

47.9

(45.7, 50.8)

2

Prostate

10.6

(7.8, 14.2)

Liver

20.3

(18.8, 21.9)

Prostate

17.8

(16.1, 19.8)

3

Pancreas

5.8

(4.1, 8.3)

Colorectum

19.5

(18.0, 21.2)

Colorectum

16.1

(14.6, 17.8)

4

Liver

5.3

(3.6, 7.7)

Stomach

11.7

(10.5, 12.9)

Liver

11.3

(10.1, 12.7)

5

Leukemia

4.8

(3.3, 7.1)

Prostate

10.4

(9.2, 11.7)

Non-Hodgkin

9.1

(7.9, 10.4)

 

Guamanian

Native Hawaiianb

Japanese

 

All cancers

147.0

(106.5, 201.8)

All cancers

263.7

(243.7, 285.4)

All Cancers

173.7

(167.7, 179.9)

1

Lung

47.4

(28.4, 81.0)

Lung

87.7

(76.4, 100.7)

Lung

39.5

(36.7, 42.5)

2

 

nr

 

Colorectum

26.9

(20.8, 34.9)

Colorectum

25.8

(23.6, 28.3)

3

 

nr

 

Prostate

21.9

(15.7, 30.1)

Stomach

16.6

(14.8, 18.7)

4

 

nr

 

Stomach

14.1

(9.9, 20.2)

Prostate

15.2

(13.5, 17.3)

5

 

nr

 

Liver

11.8

(7.9, 17.7)

Pancreas

12.2

(10.6, 14.0)

 

Korean

Samoan

Vietnamese

 

All cancers

196.5

(186.2, 207.4)

All cancers

293.9

(247.6, 348.6)

All Cancers

159.9

(149.9, 170.7)

1

Lung

50.6

(45.3, 56.2)

Lung

74.0

(53.6, 102.9)

Lung

43.9

(38.7, 49.9)

2

Stomach

31.5

(27.5, 36.0)

Stomach

40.9

(24.1, 67.6)

Liver

33.8

(29.6, 38.8)

3

Liver

26.3

(23.0, 30.2)

Prostate

36.2

(18.9, 64.4)

Stomach

12.7

(9.8, 16.4)

4

Colorectum

17.6

(14.6, 21.3)

Liver

32.9

(19.3, 56.1)

Pancreas

8.9

(6.6, 11.9)

5

Pancreas

11.4

(9.1, 14.3)

Colorectum

31.6

(17.2, 56.0)

Colorectum

8.8

(6.6, 11.7)

aRates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following States: California, Hawaii, Illinois, New Jersey, New York, Texas, and Washington

bRates for Native Hawaiians are calculated using the one or more race/ethnicities population denominators for Hawaii only (See Materials and methods)

Abbreviations: Lung = lung and bronchus; Liver = liver and intrahepatic bile duct; Non-Hodgkin = non-Hodgkin lymphoma

Mortality rates: Women

Samoan and Native Hawaiian women had the highest overall cancer death rates (Table 6), and even exceed the cancer mortality rate for non-Hispanic white women (Table 4). Asian Indian women had the lowest overall cancer death rate. Lung cancer was the leading cause of cancer death in each female API group, with the exception of Asian Indian women, for whom breast cancer had the highest age-adjusted rate (Table 6). Native Hawaiian women had the highest lung cancer death rate of all the API groups (47.6 per 100,000; 95% CI: 40.6, 55.6), but the confidence interval included the rate seen for non-Hispanic white women. Breast cancer was among the top three cancer causes of death for each female Asian ethnic group, except Koreans, where it was in the top five. Samoan and native Hawaiian women had the highest breast cancer death rates among the API groups. Colorectal cancer was among the top four cancers in every female API group, except Guamanian and Samoan women, for whom the data were too sparse to evaluate for this cancer. Liver cancer was among the top four cancer causes of death in Chinese, Korean, and Vietnamese women and their rates exceed the liver cancer mortality rate for non-Hispanic white women (Appendix Table 2). Stomach cancer was among the top five cancer causes of death for Chinese, Native Hawaiian, Japanese, Korean, and Vietnamese women and their rates exceeded the rate in non-Hispanic white women (Appendix Table 2). The cervical cancer death rate in Vietnamese women, though not among the top five cancers, exceeded the rate in non-Hispanic white women (Appendix Table 2).
Table 6

Top five age-adjusted cancer mortality ratesa and 95% CI by Asian or Pacific Islander subgroup, 1998–2002: Women

Rank

Asian Indian

Chinese

Filipina

 

Rate

(95% CI)

 

Rate

(95% CI)

 

Rate

(95% CI)

 

All cancers

67.4

(62.2, 73.1)

All cancers

107.7

(104.5, 110.9)

All Cancers

96.1

(92.8, 99.5)

1

Breast

11.2

(9.4, 13.5)

Lung

23.8

(22.4, 25.4)

Breast

17.2

(15.9, 18.6)

2

Lung

6.4

(4.8, 8.5)

Colorectum

12.8

(11.7, 13.9)

Lung

17.2

(15.8, 18.7)

3

Colorectum

5.3

(3.8, 7.3)

Breast

12.3

(11.3, 13.4)

Colorectum

9.0

(8.0, 10.1)

4

Ovary

5.0

(3.7, 6.8)

Liver

7.4

(6.5, 8.2)

Pancreas

6.3

(5.4, 7.2)

5

Pancreas

3.5

(2.4, 5.2)

Stomach

7.3

(6.5, 8.2)

Ovary

5.6

(4.9, 6.5)

 

Guamanian

Native Hawaiianb

Japanese

 

All cancers

98.5

(69.5, 138.8)

All cancers

198.9

(184.4, 214.4)

All Cancers

117.0

(112.9, 121.4)

1

nr

  

Lung

47.6

(40.6, 55.6)

Lung

19.7

(18.1, 21.5)

2

nr

  

Breast

33.5

(27.9, 40.1)

Colorectal

15.3

(13.8, 17.0)

3

nr

  

Pancreas

16.8

(12.7, 21.8)

Breast

15.1

(13.6, 16.9)

4

nr

  

Colorectum

13.1

(9.5, 17.7)

Pancreas

10.6

(9.4, 12.1)

5

nr

  

Stomach

10.3

(9.5, 17.7)

Stomach

10.2

(9.0, 11.6)

 

Korean

Samoan

Vietnamese

 

All cancers

108.2

(102.6, 114.1)

All cancers

209.3

(176.5, 248.2)

All Cancers

97.8

(91.2, 104.9)

1

Lung

20.7

(18.2, 23.4)

Lung

42.0

(27.1, 63.7)

Lung

20.2

(17.1, 23.7)

2

Stomach

14.5

(12.5, 16.8)

Breast

36.2

(24.0, 54.9)

Liver

10.9

(8.8, 13.6)

3

Colorectum

12.1

(10.3, 14.2)

nr

  

Breast

7.6

(6.1, 9.5)

4

Liver

11.7

(9.9, 13.7)

nr

  

Colorectum

7.4

(5.6, 9.7)

5

Breast

7.8

(6.5, 9.3)

nr

  

Stomach

7.0

(5.3, 9.2)

aRates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following States: California, Hawaii, Illinois, New Jersey, New York, Texas, and Washington

bRates for Native Hawaiians are calculated using the one or more race/ethnicities population denominators for Hawaii only (See Materials and methods)

Abbreviations: Lung = lung and bronchus; Liver = liver and intrahepatic bile duct; Non-Hodgkin = non-Hodgkin lymphoma

Discussion

Possible disparities in cancer incidence and mortality were identified for some of the API populations studied, using non-Hispanic whites as the referent. Liver cancer incidence and death rates were notably high among Chinese, Kampuchean, Korean, Laotian, Samoan, and Vietnamese men; and the rates for all API groups and both sexes in our study exceeded those for non-Hispanic white men and women. Infection with hepatitis B and C viruses is the major cause of liver cancer and individuals migrating from Asian, Middle Eastern, and African countries, where the viruses are endemic have been widely reported to be at increased risk for this cancer [28]. Stomach cancer incidence and death rates were higher for many of the API groups in our study when compared to rates for non-Hispanic whites. Asian Indian/Pakistani, and Filipinos were the exceptions, with their rates being closer to those for non-Hispanic whites. Studies of migrant populations suggest that exposure early in life to Helicobacter pylori plays a role in stomach cancer risk, in addition to possible dietary factors [29]. A majority of the API cancer patients in our study were born outside of the U.S., with the exception of Japanese-Americans and Native Hawaiians (data not shown). Birthplace information was missing from registry records, however, for about 28% of the API in this study. Incidence and death rates for nasopharyngeal cancer among Chinese, Filipino, and Vietnamese groups in our study are several times the magnitude of rates seen in other U.S. racial/ethnic groups [30]. Rates may also be high in other U.S. API groups, but the number of cases in our study is too small to provide precise estimates. Chinese and several Southeast populations—including Filipinos, Thais, and Vietnamese—have previously been reported at increased risk for this cancer [31] and rates are known to remain high among Chinese immigrants to the U.S. and other countries [32]. Consumption of preserved foods beginning at an early age is frequent among these groups and has been associated with this cancer [31].

The low rates of lung, colorectal, and stomach cancers we observed among Asian Indians, either living in India or residing in other countries, have also been reported by others [3335]. Factors such as lower tobacco use and components of the South Asian diet have been suggested as playing important roles in these patterns [3638]. Breast cancer was a leading cancer among API women in our study, as it is in other racial/ethnic groups [39], but the breast cancer incidence rate in each API group, with the exception of native Hawaiians, was lower than that for non-Hispanic white women.

Though based on small numbers, we note that Samoan women had a smaller percentage of breast cancers diagnosed at an early stage and their breast cancer death rate was among the highest of the API groups. Others have reported low screening rates among Samoan women and note the need for targeted efforts to improve doctor–patient communication on prevention behavior [40, 41]. Samoan men had lower percentages of colorectal and prostate cancers diagnosed at an early stage and this may be reflected in their higher mortality rates for these cancers. Increased efforts to improve screening for these cancers in specific API groups may be needed. These results are based on small numbers of deaths among Samoans, however, and need to be confirmed in other studies. Furthermore, our findings must be interpreted cautiously, since the geographic coverage of the API study populations included in the incidence and mortality analyses are somewhat different.

Limitations of the source data must be recognized when analyzing racial/ethnic patterns of disease. Evaluations of the accuracy of cancer registry data on race/ethnicity, which is extracted from patient medical records, have shown varying levels of misclassification [4247]. A recent comparison of self-reported race/ethnicity obtained from interview studies with that from registry records was conducted by the Greater Bay Area Cancer Registry (comprising the San Francisco/Oakland and San Jose/Monterey regions of California) [42]. They found that sensitivities and positive predictive values (PV+) were high for non-Hispanic Whites and Blacks and were moderately high for Chinese (sensitivity = 77%, PV+ = 92%) leading to a 16% underestimate of Chinese cases. For Japanese and Filipinos, they reported comparable results of about 80% for both sensitivity and PV+; while for Vietnamese they reported low sensitivity (47%) and moderate PV+ (75%), yielding a 37% underestimate for this group. There were too few Koreans, South Asians (mostly Asian Indians), Laotians, Kampucheans, and Pacific Islanders to provide reliable estimates of sensitivity or PV+ in their study. In addition, about 7% of the diagnosed cancer cases in our incidence analysis were classified as Asian NOS or Pacific Islander NOS, thereby depressing the rates we reported for specific Asian or Pacific Islander groups. To address this problem, collaborative efforts are underway between the SEER Program registries and the National Association of Central Cancer Registries to improve how central registries classify cancer patients into specific Asian or Pacific Islander groups by using name lists and information on birthplace. Similar misclassification problems have been identified for death certificate information on race/ethnicity and have been reported to result in an 11% underestimate of mortality rates for the API group as a whole [48]. The impact of nonspecific API race on the mortality rates in our study is small, however, since less than 0.1% of deaths were coded as “API, NOS.” These limitations suggest that the API rates we have reported are generally biased downward, in spite of the fact that we used the single race population denominators in our rate calculations.

In conclusion, we found some evidence for cancer health disparities between specific API populations and non-Hispanic whites. The addition of population denominators for detailed API groups to SEER*Stat software developed by the National Cancer Institute’s Surveillance Research Program will enable public health researchers to utilize SEER databases to further investigate cancer incidence and mortality rates among these groups in the US [8]. Additional studies might include analyses that incorporate tumor characteristics (e.g., cancer subsite, histology, and grade) or other sociodemographic factors when examining racial/ethnic differences in cancer patterns.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Appendix

Appendix 1 Age-adjusted incidence ratesa for major cancersb by race/ethnicity and sex, 1998–2002

 

Count

Rate based on single race/ethnicity alone denominator

Rate based on one or more race/ethnicities denominator

Rate

95% CI

Rate

95% CI

 

LL

UL

 

LL

UL

Asian Indian & Pakistani/Men

All Sites

2,314

292.1

277.3

307.9

255.5

242.5

269.1

Prostate

701

98.4

90.0

107.7

86.1

78.8

94.2

Lung and bronchus

207

30.8

25.7

36.8

26.9

22.5

32.1

Colon and rectum

199

23.1

19.3

27.9

20.3

17.0

24.4

Lymphoma—Non-Hodgkin

142

15.8

12.5

20.1

13.8

11.0

17.5

Urinary bladder

98

15.8

12.1

20.5

13.8

10.6

17.8

Leukemia

138

12.2

9.5

15.9

10.7

8.3

13.9

Oral cavity (excl nasopharynx)

102

11.4

8.7

15.1

10.0

7.6

13.2

Liver and intrahepatic bile duct

60

8.7

6.2

12.3

7.6

5.4

10.7

Kidney and renal pelvis

64

8.4

6.0

11.7

7.3

5.3

10.2

Stomach

61

8.2

5.8

11.6

7.1

5.1

10.1

Pancreas

52

8.0

5.4

11.7

7.0

4.8

10.2

Brain and other nervous system

84

6.7

5.0

9.3

5.9

4.4

8.1

Myeloma

43

4.8

3.3

7.3

4.2

2.9

6.4

Larynx

23

4.5

2.5

7.7

3.9

2.2

6.6

Esophagus

27

3.6

2.1

6.2

3.2

1.9

5.4

Thyroid

40

2.7

1.8

4.7

2.4

1.6

4.1

Testis

38

2.3

1.3

4.5

2.0

1.2

3.9

Lymphoma—Hodgkin

36

2.0

1.4

3.7

1.7

1.2

3.2

Asian Indian & Pakistani/Women

All sites

2,229

238.1

226.7

250.2

208.2

198.4

218.6

Breast

864

82.1

76.1

88.8

72.3

67.0

78.1

Colon and rectum

147

18.8

15.5

23.0

16.4

13.5

19.9

Corpus and uterus, NOS

127

13.5

10.9

16.7

11.8

9.6

14.6

Lung and bronchus

90

13.1

10.2

16.9

11.3

8.9

14.5

Ovary

123

12.0

9.7

15.1

10.6

8.6

13.2

Lymphoma—Non-Hodgkin

92

9.4

7.3

12.3

8.2

6.4

10.7

Leukemia

86

9.0

6.8

12.0

7.8

5.9

10.4

Thyroid

111

8.3

6.6

10.7

7.3

5.9

9.4

Cervix Uteri

59

6.1

4.5

8.4

5.4

4.0

7.4

Brain and other nervous system

56

5.6

4.0

8.1

4.9

3.5

7.0

Esophagus

35

5.2

3.4

8.0

4.5

3.0

6.8

Oral cavity (excl nasopharynx)

41

5.0

3.3

7.6

4.3

2.9

6.5

Stomach

31

4.7

3.0

7.2

4.1

2.6

6.2

Pancreas

31

4.4

2.8

6.8

3.8

2.4

5.9

Myeloma

31

4.3

2.7

6.9

3.7

2.3

5.9

Liver and intrahepatic bile duct

31

3.9

2.6

6.2

3.4

2.2

5.4

Gallbladder

25

3.5

2.1

5.9

3.1

1.9

5.1

Urinary bladder

23

3.0

1.8

5.1

2.6

1.6

4.4

Kidney and renal pelvis

26

2.8

1.8

4.7

2.5

1.6

4.1

Lymphoma—Hodgkin

23

1.8

1.0

3.6

1.6

0.8

3.1

Chinese/Men

All sites

9,175

348.8

341.5

356.2

318.9

312.2

325.7

Prostate

2,209

84.8

81.2

88.5

78.2

74.9

81.7

Colon and rectum

1,400

54.0

51.2

57.0

49.6

46.9

52.3

Lung and bronchus

1,340

53.0

50.1

56.0

48.9

46.2

51.7

Liver and intrahepatic bile duct

666

24.0

22.1

25.9

21.7

20.1

23.5

Stomach

461

18.3

16.6

20.2

16.8

15.3

18.5

Urinary bladder

389

15.7

14.1

17.4

14.5

13.1

16.1

Lymphoma—Non-Hodgkin

401

14.8

13.4

16.4

13.5

12.1

14.9

Pancreas

243

9.8

8.5

11.1

9.0

7.9

10.3

Nasopharynx

277

8.9

7.9

10.1

7.9

7.0

8.9

Leukemia

231

8.7

7.6

10.0

7.6

6.6

8.7

Kidney and renal pelvis

192

7.2

6.2

8.4

6.6

5.7

7.7

Oral cavity (excl nasopharynx)

166

6.2

5.3

7.3

5.7

4.8

6.6

Esophagus

124

4.5

3.7

5.4

4.1

3.4

5.0

Brain and other nervous system

123

4.3

3.5

5.1

3.7

3.0

4.4

Thyroid

96

3.2

2.5

3.9

2.8

2.2

3.5

Larynx

78

3.0

2.3

3.8

2.7

2.2

3.5

Myeloma

74

2.7

2.1

3.5

2.5

2.0

3.2

Testis

57

1.7

1.3

2.2

1.4

1.1

1.9

Lymphoma—Hodgkin

40

1.3

0.9

1.8

1.1

0.8

1.6

Melanoma of the skin

35

1.2

0.8

1.7

1.1

0.8

1.6

Gallbladder

24

0.9

0.6

1.4

0.9

0.6

1.3

Chinese/Women

All Sites

8,817

270.4

264.7

276.2

243.5

238.4

248.7

Breast

2,652

77.6

74.6

80.6

69.3

66.6

72.0

Colon and rectum

1,257

40.2

38.0

42.5

36.7

34.7

38.8

Lung and bronchus

923

29.7

27.8

31.7

27.2

25.5

29.0

Corpus and uterus, NOS

406

12.0

10.9

13.3

10.8

9.8

11.9

Stomach

344

11.1

10.0

12.4

10.2

9.1

11.3

Thyroid

358

10.0

9.0

11.2

8.8

7.9

9.7

Ovary

335

10.0

8.9

11.1

8.8

7.9

9.9

Lymphoma—Non-Hodgkin

316

10.0

8.9

11.1

9.0

8.0

10.0

Liver and intrahepatic bile duct

258

8.2

7.3

9.3

7.5

6.6

8.5

Pancreas

209

6.8

5.9

7.8

6.3

5.4

7.2

Leukemia

188

5.9

5.1

6.9

5.1

4.4

6.0

Cervix Uteri

193

5.6

4.9

6.5

5.0

4.3

5.8

Urinary bladder

133

4.4

3.7

5.3

4.1

3.4

4.8

Kidney and renal pelvis

126

4.0

3.3

4.8

3.6

3.0

4.3

Oral cavity (excl nasopharynx)

119

3.6

3.0

4.4

3.3

2.7

3.9

Nasopharynx

125

3.5

2.9

4.2

3.1

2.6

3.7

Brain and other nervous system

90

2.7

2.2

3.4

2.3

1.9

2.9

Myeloma

76

2.5

2.0

3.1

2.3

1.8

2.9

Gallbladder

41

1.3

1.0

1.8

1.2

0.9

1.7

Esophagus

32

1.0

0.7

1.5

0.9

0.6

1.3

Melanoma of the skin

32

1.0

0.7

1.4

0.9

0.6

1.2

Lymphoma—Hodgkin

22

0.7

0.4

1.0

0.6

0.4

0.9

Filipino/Men

All Sites

9,206

393.2

385.1

401.5

357.3

349.8

364.9

Prostate

2,768

121.9

117.3

126.6

111.6

107.4

115.9

Lung and bronchus

1,665

72.5

69.0

76.1

66.2

63.0

69.6

Colon and rectum

1,194

50.4

47.5

53.4

45.9

43.2

48.6

Lymphoma—Non-Hodgkin

467

19.4

17.7

21.4

17.5

15.9

19.3

Liver and intrahepatic bile duct

413

17.2

15.5

19.0

15.6

14.1

17.2

Urinary bladder

267

12.4

10.9

14.0

11.4

10.0

12.9

Leukemia

249

10.0

8.8

11.4

8.7

7.6

10.0

Stomach

216

9.4

8.1

10.8

8.6

7.4

9.8

Pancreas

206

9.2

8.0

10.6

8.4

7.3

9.7

Kidney and renal pelvis

232

9.2

8.0

10.5

8.3

7.3

9.5

Thyroid

163

6.1

5.1

7.1

5.4

4.6

6.3

Myeloma

131

5.8

4.9

6.9

5.3

4.4

6.4

Oral cavity (excl nasopharynx)

138

5.8

4.8

6.9

5.2

4.4

6.2

Nasopharynx

129

4.8

4.0

5.7

4.3

3.5

5.1

Brain and other nervous system

100

3.8

3.1

4.7

3.2

2.6

4.0

Larynx

65

2.9

2.2

3.7

2.6

2.0

3.4

Esophagus

65

2.7

2.1

3.5

2.5

1.9

3.2

Testis

56

1.8

1.3

2.4

1.5

1.1

2.0

Lymphoma—Hodgkin

43

1.5

1.1

2.1

1.3

1.0

1.9

Melanoma of the skin

27

1.2

0.8

1.8

1.1

0.7

1.6

Gallbladder

22

1.0

0.6

1.6

0.9

0.6

1.5

Breast

18

0.9

0.5

1.4

0.8

0.5

1.3

Kaposi Sarcoma

24

0.8

0.5

1.3

0.7

0.5

1.1

Filipina/Women

All Sites

9,847

291.1

285.3

297.1

264.3

259.0

269.8

Breast

3,610

100.4

97.1

103.8

91.1

88.1

94.2

Colon and rectum

935

29.4

27.5

31.4

27.0

25.2

28.9

Lung and bronchus

802

26.0

24.1

27.9

23.9

22.3

25.8

Corpus and uterus, NOS

667

18.6

17.2

20.1

16.9

15.6

18.3

Thyroid

652

17.7

16.4

19.2

15.7

14.5

17.0

Lymphoma—Non-Hodgkin

379

12.2

11.0

13.6

11.2

10.0

12.4

Ovary

369

10.5

9.5

11.7

9.5

8.5

10.6

Cervix Uteri

361

10.0

9.0

11.2

9.0

8.1

10.1

Pancreas

233

7.7

6.7

8.9

7.1

6.2

8.2

Leukemia

183

5.8

4.9

6.7

5.0

4.2

5.8

Stomach

162

5.6

4.7

6.6

5.1

4.4

6.1

Liver and intrahepatic bile duct

150

5.1

4.3

6.0

4.7

3.9

5.6

Kidney and renal pelvis

162

4.8

4.1

5.7

4.4

3.7

5.1

Myeloma

126

4.2

3.5

5.0

3.9

3.2

4.7

Oral cavity (excl nasopharynx)

127

4.0

3.3

4.8

3.6

3.0

4.4

Brain and other nervous system

77

2.4

1.9

3.1

2.1

1.6

2.6

Urinary bladder

68

2.4

1.8

3.1

2.2

1.7

2.9

Lymphoma—Hodgkin

55

1.6

1.2

2.1

1.3

1.0

1.8

Nasopharynx

55

1.6

1.2

2.1

1.4

1.0

1.9

Gallbladder

43

1.4

1.0

2.0

1.3

0.9

1.8

Esophagus

34

1.1

0.8

1.6

1.0

0.7

1.5

Melanoma of the skin

27

0.8

0.5

1.2

0.7

0.5

1.1

Guamanian/Men

All Sites

79

252.1

189.8

336.7

197.8

148.8

264.7

Prostate

32

131.5

85.0

202.4

102.6

66.3

158.6

Guamanian/Women

All Sites

77

175.6

132.7

233.8

136.7

103.9

180.3

Breast

25

45.0

28.3

78.1

35.8

22.4

60.5

Lung and bronchus

16

40.7

22.4

76.4

33.0

18.2

60.1

Native Hawaiian (HI only)/Men c

All Sites

1,664

531.6

503.7

561.1

Prostate

328

119.7

106.1

135.1

Lung and bronchus

329

109.8

97.4

123.9

Colon and rectum

198

65.7

56.1

77.1

Urinary bladder

55

21.2

15.3

29.1

Lymphoma—Non-Hodgkin

68

19.6

14.8

26.3

Stomach

62

18.8

14.1

25.3

Leukemia

58

16.3

11.8

22.7

Liver and intrahepatic bile duct

54

16.3

11.8

22.6

Kidney and renal pelvis

54

_

_

_

15.5

11.4

21.4

Pancreas

48

_

_

_

15.1

10.8

21.4

Oral cavity (excl nasopharynx)

53

_

_

_

13.7

10.1

19.2

Esophagus

33

_

_

_

9.6

6.4

14.7

Myeloma

26

_

_

_

8.6

5.3

14.0

Larynx

22

_

_

_

6.9

4.2

11.7

Brain and other nervous system

29

_

_

_

6.0

3.8

10.2

Testis

29

_

_

_

5.3

3.5

9.0

Thyroid

23

_

_

_

5.1

3.1

9.1

Native Hawaiian (HI only)/Women c

All Sites

1,979

_

_

_

488.5

466.5

511.3

Breast

736

_

_

_

175.8

163.0

189.4

Lung and bronchus

258

_

_

_

69.7

61.2

79.1

Colon and rectum

166

_

_

_

44.0

37.3

51.6

Corpus and uterus, NOS

162

_

_

_

37.5

31.9

44.1

Pancreas

68

_

_

_

18.6

14.3

23.9

Stomach

51

_

_

_

14.5

10.7

19.4

Thyroid

61

_

_

_

12.6

9.5

16.5

Cervix Uteri

56

_

_

_

12.3

9.2

16.4

Ovary

50

_

_

_

12.1

8.9

16.3

Lymphoma—Non-Hodgkin

47

_

_

_

11.7

8.5

16.0

Leukemia

45

_

_

_

9.4

6.7

13.1

Liver and intrahepatic bile duct

27

_

_

_

7.7

5.0

11.5

Urinary bladder

24

_

_

_

6.8

4.3

10.4

Myeloma

24

_

_

_

6.8

4.3

10.4

Oral cavity (excl nasopharynx)

25

_

_

_

5.8

3.7

8.9

Kidney and renal pelvis

22

_

_

5.4

3.4

8.5

Brain and other nervous system

25

_

_

5.0

3.2

7.9

Japanese/Men

All Sites

7,765

422.4

412.8

432.3

389.4

380.7

398.3

Prostate

2,211

115.0

110.1

120.1

108.9

104.3

113.6

Colon and rectum

1,402

75.9

71.9

80.2

70.7

67.0

74.6

Lung and bronchus

952

49.8

46.6

53.3

47.0

44.0

50.1

Stomach

542

29.3

26.9

32.1

27.6

25.3

30.1

Urinary bladder

438

22.9

20.8

25.4

21.6

19.6

23.8

Lymphoma—Non-Hodgkin

323

18.3

16.3

20.6

16.4

14.7

18.4

Pancreas

231

12.5

10.9

14.4

11.8

10.3

13.5

Kidney and renal pelvis

210

11.5

10.0

13.4

10.6

9.2

12.1

Liver and intrahepatic bile duct

199

11.4

9.8

13.3

10.3

8.9

11.9

Leukemia

173

11.4

9.6

13.5

8.8

7.5

10.2

Oral cavity (excl nasopharynx)

155

8.5

7.2

10.2

7.9

6.7

9.3

Esophagus

131

7.5

6.2

9.1

6.9

5.8

8.2

Testis

63

4.6

3.5

6.0

3.3

2.6

4.3

Brain and other nervous system

59

4.3

3.2

5.8

3.0

2.3

4.0

Thyroid

53

3.3

2.4

4.5

2.8

2.1

3.7

Larynx

57

3.1

2.4

4.2

2.9

2.2

3.8

Myeloma

52

2.8

2.1

3.8

2.6

1.9

3.4

Melanoma of the skin

35

2.1

1.5

3.2

1.8

1.3

2.6

Lymphoma—Hodgkin

17

1.5

0.8

2.5

0.9

0.5

1.5

Japanese/Women

All Sites

8,306

342.2

334.5

350.2

310.4

303.5

317.3

Breast

2,890

126.5

121.7

131.5

113.7

109.5

118.1

Colon and rectum

1,373

51.9

49.1

55.0

48.5

45.9

51.2

Lung and bronchus

691

24.7

22.8

26.8

23.4

21.6

25.3

Corpus and uterus, NOS

454

20.4

18.5

22.6

18.3

16.6

20.1

Stomach

414

15.0

13.6

16.8

14.2

12.8

15.7

Lymphoma—Non-Hodgkin

313

12.2

10.8

13.9

11.2

9.9

12.5

Pancreas

309

11.3

10.0

12.9

10.7

9.5

12.0

Ovary

242

11.1

9.6

12.8

9.7

8.5

11.1

Thyroid

156

8.2

6.9

9.8

6.8

5.7

8.0

Liver and intrahepatic bile duct

219

7.9

6.9

9.3

7.4

6.4

8.5

Leukemia

147

7.0

5.8

8.6

5.8

4.9

6.9

Cervix Uteri

118

6.2

5.1

7.6

5.2

4.3

6.3

Kidney and renal pelvis

122

4.8

4.0

6.0

4.4

3.6

5.3

Urinary bladder

130

4.7

3.9

5.8

4.4

3.7

5.3

Oral cavity (excl nasopharynx)

99

4.2

3.4

5.4

3.8

3.1

4.7

Brain and other nervous system

44

2.8

1.9

4.1

1.9

1.4

2.6

Myeloma

56

2.2

1.6

3.1

2.0

1.5

2.7

Melanoma of the skin

43

2.0

1.5

3.0

1.8

1.3

2.5

Esophagus

34

1.3

0.9

2.1

1.2

0.8

1.7

Gallbladder

23

0.9

0.6

1.6

0.8

0.5

1.3

Kampuchean/Men

All Sites

319

372.0

325.3

425.5

316.0

276.4

361.5

Lung and bronchus

56

82.6

60.1

112.6

69.3

50.6

94.7

Liver and intrahepatic bile duct

59

49.1

36.3

68.5

41.6

30.9

58.2

Prostate

27

39.7

25.0

62.2

33.6

21.3

52.8

Colon and rectum

30

30.0

18.3

49.5

25.8

15.7

42.7

Stomach

16

23.8

12.1

44.3

20.6

10.4

38.5

Lymphoma—Non-Hodgkin

23

22.1

12.8

39.2

18.6

10.8

33.1

Kampuchean/Women

All Sites

278

212.3

185.9

242.4

180.7

158.2

206.3

Breast

58

38.2

28.3

51.8

32.5

24.1

44.1

Lung and bronchus

26

24.6

15.6

37.8

21.0

13.3

32.4

Colon and rectum

25

21.1

13.1

33.2

17.9

11.2

28.3

Cervix Uteri

22

15.3

9.3

25.3

13.0

7.9

21.5

Liver and intrahepatic bile duct

16

14.1

7.6

24.9

12.0

6.5

21.3

Thyroid

20

13.4

7.8

23.2

11.4

6.6

19.7

Korean/Men

All Sites

2,832

372.6

357.4

388.4

356.2

341.6

371.3

Lung and bronchus

414

61.1

54.8

68.2

58.6

52.5

65.4

Colon and rectum

437

55.9

50.2

62.2

53.5

48.1

59.6

Prostate

383

55.7

49.8

62.3

53.5

47.8

59.8

Stomach

384

50.0

44.6

56.2

47.9

42.7

53.8

Liver and intrahepatic bile duct

319

35.9

31.6

40.8

34.3

30.2

39.0

Urinary bladder

106

14.6

11.7

18.3

14.0

11.2

17.6

Lymphoma—Non-Hodgkin

112

14.5

11.7

18.1

13.8

11.1

17.2

Pancreas

88

12.5

9.7

16.0

12.0

9.3

15.4

Kidney and renal pelvis

70

9.4

7.1

12.4

8.9

6.7

11.7

Oral cavity (excl nasopharynx)

69

8.6

6.5

11.4

8.2

6.2

10.9

Leukemia

67

8.1

6.1

10.9

7.5

5.6

10.1

Esophagus

35

5.2

3.4

7.7

4.9

3.3

7.4

Gallbladder

22

4.3

2.5

7.0

4.1

2.4

6.7

Thyroid

39

3.7

2.6

5.6

3.5

2.4

5.3

Larynx

26

3.2

2.0

5.2

3.1

2.0

5.0

Brain and other nervous system

32

2.9

2.0

4.6

2.7

1.8

4.3

Myeloma

17

2.1

1.1

4.0

2.0

1.1

3.8

Nasopharynx

16

1.7

0.8

3.3

1.6

0.8

3.2

Korean/Women

All Sites

3,135

254.5

245.2

264.1

243.5

234.6

252.7

Breast

779

53.5

49.7

57.6

51.0

47.4

54.9

Colon and rectum

408

35.9

32.3

39.8

34.5

31.1

38.3

Lung and bronchus

300

27.5

24.3

31.0

26.5

23.5

29.9

Stomach

294

26.3

23.3

29.7

25.3

22.4

28.6

Liver and intrahepatic bile duct

164

14.4

12.2

17.0

13.9

11.8

16.4

Cervix Uteri

142

10.8

9.0

12.8

10.3

8.6

12.3

Thyroid

145

9.8

8.2

11.7

9.2

7.8

11.0

Pancreas

87

8.4

6.6

10.5

8.1

6.4

10.1

Corpus and uterus, NOS

115

8.0

6.6

9.8

7.7

6.3

9.3

Ovary

102

7.5

6.1

9.3

7.2

5.8

8.9

Lymphoma—Non-Hodgkin

82

7.4

5.8

9.3

7.1

5.6

9.0

Urinary bladder

47

4.9

3.6

6.7

4.8

3.4

6.4

Leukemia

61

4.6

3.5

6.1

4.2

3.2

5.6

Kidney and renal pelvis

49

4.2

3.1

5.7

4.0

2.9

5.4

Gallbladder

36

3.4

2.4

4.9

3.3

2.3

4.7

Oral cavity (excl nasopharynx)

35

2.8

1.9

4.0

2.6

1.8

3.8

Brain and other nervous system

30

2.4

1.6

3.5

2.1

1.4

3.2

Myeloma

20

2.0

1.2

3.2

1.9

1.2

3.1

Laotian/Men

All Sites

376

407.2

360.7

460.3

357.2

316.0

404.4

Lung and bronchus

64

87.3

64.9

117.4

76.6

56.8

103.6

Liver and intrahepatic bile duct

80

79.4

60.7

105.0

69.8

53.2

92.8

Stomach

22

33.1

19.1

55.8

29.6

16.9

50.3

Prostate

21

30.9

18.2

51.9

27.0

15.9

45.9

Colon and rectum

30

30.2

19.4

48.8

26.2

16.9

42.8

Pancreas

21

21.6

12.5

38.7

18.8

10.9

34.1

Lymphoma—Non-Hodgkin

26

20.3

11.6

37.0

17.9

10.1

33.3

Laotian/Women

All Sites

299

297.9

263.0

337.1

260.5

229.9

294.7

Lung and bronchus

40

44.4

31.2

62.3

38.8

27.3

54.4

Breast

45

36.9

26.5

51.5

32.3

23.2

45.0

Colon and rectum

24

27.5

17.1

42.7

24.0

15.0

37.3

Cervix Uteri

28

24.8

16.0

38.0

21.7

14.0

33.3

Liver and intrahepatic bile duct

24

23.1

14.5

36.4

20.3

12.7

31.9

Samoan/Men

All Sites

356

566.7

498.8

645.5

471.2

415.1

535.6

Prostate

77

144.1

110.0

190.4

120.6

92.2

158.0

Lung and bronchus

70

111.9

84.4

151.1

94.1

71.0

126.0

Liver and intrahepatic bile duct

35

54.5

35.2

86.9

45.1

29.4

70.3

Stomach

30

53.0

33.2

86.1

44.7

28.0

71.3

Colon and rectum

31

43.1

26.6

72.8

35.8

22.0

59.3

Leukemia

19

23.0

10.9

49.7

18.8

8.6

39.8

Samoan/Women

All Sites

396

472.0

421.5

528.6

394.5

352.2

441.9

Breast

94

102.5

81.7

129.5

86.2

68.6

108.9

Corpus and uterus, NOS

67

66.1

50.3

88.2

55.2

41.8

73.7

Lung and bronchus

41

56.9

39.6

81.3

48.1

33.4

68.6

Colon and rectum

28

38.6

24.1

60.5

32.2

20.2

50.3

Cervix Uteri

19

18.1

10.6

32.7

15.1

8.8

27.3

Tongan/Men

All Sites

95

428.8

329.9

555.9

367.4

283.6

473.6

Lung and bronchus

18

107.0

55.2

193.0

87.9

46.3

156.2

Prostate

16

85.0

44.5

157.4

74.7

39.3

135.5

Tongan/Women

All Sites

139

504.7

414.1

616.6

430.5

352.8

526.5

Breast

35

118.0

78.1

181.2

100.8

66.7

154.9

Corpus and uterus, NOS

26

91.2

56.4

150.1

77.8

48.0

128.3

Vietnamese/Men

All Sites

3,020

374.3

358.5

390.9

351.7

336.9

367.2

Lung and bronchus

543

72.3

65.3

80.2

68.0

61.4

75.3

Prostate

415

59.1

52.8

66.3

55.6

49.6

62.3

Liver and intrahepatic bile duct

493

55.5

49.9

62.0

52.4

47.1

58.4

Colon and rectum

338

41.2

36.1

47.1

38.8

34.0

44.3

Stomach

178

25.6

21.2

30.9

24.0

19.9

28.9

Lymphoma—Non-Hodgkin

143

14.7

11.9

18.5

13.8

11.1

17.3

Urinary bladder

86

13.6

10.4

17.8

12.7

9.7

16.6

Pancreas

86

11.4

8.7

15.0

10.7

8.2

14.1

Leukemia

84

9.9

7.5

13.2

9.2

7.0

12.3

Oral cavity (excl nasopharynx)

69

7.7

5.6

10.7

7.2

5.3

10.0

Nasopharynx

75

6.7

5.1

9.1

6.3

4.8

8.6

Esophagus

43

6.5

4.4

9.7

6.1

4.1

9.1

Kidney and renal pelvis

44

5.0

3.5

7.5

4.7

3.3

7.1

Brain and other nervous system

52

4.9

3.4

7.4

4.6

3.2

6.9

Larynx

29

4.3

2.6

7.0

4.0

2.5

6.6

Thyroid

48

4.0

2.8

6.2

3.8

2.7

5.8

Myeloma

23

2.7

1.6

4.7

2.5

1.5

4.5

Testis

19

1.2

0.7

2.8

1.1

0.7

2.6

Vietnamese/Women

All Sites

2,720

270.6

259.6

282.2

254.9

244.5

265.8

Breast

647

52.8

48.6

57.5

49.9

45.9

54.3

Lung and bronchus

290

34.4

30.3

39.1

32.5

28.5

36.9

Colon and rectum

302

33.3

29.3

37.8

31.4

27.6

35.6

Cervix Uteri

189

16.8

14.3

19.8

15.9

13.6

18.7

Liver and intrahepatic bile duct

146

16.8

14.0

20.1

15.8

13.2

18.9

Stomach

110

13.8

11.1

17.0

13.0

10.5

16.0

Thyroid

174

13.3

11.2

15.8

12.5

10.6

14.8

Lymphoma—Non-Hodgkin

116

12.0

9.7

14.8

11.3

9.1

13.9

Pancreas

81

10.0

7.8

12.7

9.4

7.3

12.0

Ovary

100

8.6

6.9

10.8

8.1

6.5

10.2

Corpus and uterus, NOS

95

8.2

6.5

10.4

7.8

6.2

9.8

Leukemia

70

6.6

4.9

8.7

6.1

4.6

8.1

Oral cavity (excl nasopharynx)

46

5.0

3.5

7.0

4.7

3.3

6.6

Myeloma

34

4.3

2.9

6.2

4.0

2.7

5.9

Urinary bladder

24

3.6

2.3

5.6

3.4

2.1

5.2

Brain and other nervous system

31

2.7

1.7

4.1

2.5

1.6

3.8

Nasopharynx

27

2.3

1.5

3.7

2.2

1.4

3.5

Gallbladder

19

2.2

1.3

3.7

2.1

1.2

3.5

Kidney and renal pelvis

16

1.7

0.9

3.1

1.6

0.9

2.9

Non − Hispanic White/Men d

All Sites

649,731

587.0

585.6

588.5

   

Prostate

189,678

170.0

169.3

170.8

   

Lung and bronchus

98,625

89.2

88.7

89.8

   

Colon and rectum

71,656

65.6

65.2

66.1

   

Urinary bladder

46,682

43.0

42.6

43.4

   

Melanoma of the skin

32,981

29.3

29.0

29.6

   

Lymphoma—Non-Hodgkin

27,294

24.6

24.3

24.9

   

Kidney and renal pelvis

19,671

17.5

17.2

17.7

   

Leukemia

18,718

17.3

17.1

17.6

   

Oral cavity (excl nasopharynx)

18,462

16.2

16.0

16.5

   

Pancreas

14,220

13.0

12.8

13.2

   

Stomach

10,797

9.9

9.7

10.1

   

Brain and other nervous system

9,893

8.9

8.7

9.1

   

Esophagus

9,079

8.1

8.0

8.3

   

Larynx

8,101

7.1

7.0

7.3

   

Testis

7,816

7.0

6.9

7.2

   

Liver and intrahepatic bile duct

7,445

6.7

6.5

6.8

   

Myeloma

7,264

6.6

6.4

6.8

   

Thyroid

4,996

4.3

4.2

4.5

   

Lymphoma—Hodgkin

3,833

3.5

3.4

3.6

   

Kaposi Sarcoma

1,247

1.1

1.1

1.2

   

Gallbladder

768

0.7

0.7

0.8

   

Nasopharynx

717

0.6

0.6

0.7

   

Non − Hispanic White/Women d

All Sites

617,158

448.5

447.3

449.6

   

Breast

195,231

145.2

144.5

145.8

   

Lung and bronchus

83,387

59.0

58.6

59.4

   

Colon and rectum

70,298

47.6

47.2

47.9

   

Corpus and uterus, NOS

35,224

26.0

25.7

26.2

   

Melanoma of the skin

24,455

19.3

19.0

19.5

   

Lymphoma—Non-Hodgkin

24,177

17.2

17.0

17.5

   

Ovary

20,736

15.3

15.1

15.5

   

Thyroid

14,103

11.8

11.6

12.0

   

Urinary bladder

15,480

10.6

10.4

10.8

   

Leukemia

13,800

10.0

9.8

10.1

   

Pancreas

14,520

9.8

9.6

9.9

   

Kidney and renal pelvis

11,787

8.5

8.4

8.7

   

Cervix Uteri

9,930

8.1

7.9

8.3

   

Oral cavity (excl nasopharynx)

8,996

6.5

6.3

6.6

   

Brain and other nervous system

7,911

6.2

6.1

6.4

   

Stomach

6,430

4.3

4.2

4.4

   

Myeloma

5,986

4.1

4.0

4.2

   

Lymphoma—Hodgkin

3,348

2.9

2.8

3.0

   

Liver and intrahepatic bile duct

3,689

2.6

2.5

2.6

   

Esophagus

3,067

2.1

2.0

2.2

   

Larynx

2,255

1.7

1.6

1.7

   

Gallbladder

1,754

1.2

1.1

1.2

   

Nasopharynx

315

0.2

0.2

0.3

   

Kaposi Sarcoma

169

0.1

0.1

0.1

   

aRates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following SEER areas: Atlanta, Detroit, Seattle/Puget Sound, CA (Los Angeles, Greater Bay Region, remainder of State), CT, HI, IA, KY, LA, NJ, NM, UT

bCancers are sorted in descending order of the rate within each race/ethnic and sex group

cRates for Native Hawaiians are calculated using only the one or more race/ethnicities population denominator (See Materials and methods)

dRates for Non-Hispanic Whites are calculated using the bridged single-race population denominator (See Materials and methods)

Appendix 2 Age-adjusted mortality ratesa for major cancersb by race/ethnicity and sex, 1998–2002

 

Count

Rate based on single race/ethnicity alone denominator

Rate based on one or more race/ethnicities denominator

Rateb

95% CI

Rateb

95% CI

 

LL

UL

 

LL

UL

Asian Indian/Male

All Sites

852

82.8

75.7

90.5

72.1

66.0

78.8

Lung and bronchus

160

17.2

14.1

21.1

15.0

12.3

18.4

Prostate

62

10.6

7.8

14.2

9.1

6.7

12.2

Pancreas

53

5.8

4.1

8.3

5.1

3.6

7.2

Liver and intrahepatic bile duct

54

5.3

3.6

7.7

4.6

3.1

6.7

Leukemia

73

4.8

3.3

7.1

4.2

2.9

6.1

Colon and rectum

48

4.1

2.6

6.3

3.6

2.3

5.4

Stomach

44

3.7

2.5

5.7

3.3

2.2

5.0

Urinary bladder

21

3.7

2.1

6.1

3.2

1.8

5.3

Lymphoma—Non-Hodgkin

40

3.7

2.4

5.7

3.2

2.1

5.0

Esophagus

33

3.5

2.2

5.7

3.1

1.9

4.9

Brain and other nervous system

55

3.3

2.3

5.1

2.9

2.0

4.4

Oral cavity (excl nasopharynx)

36

2.9

1.7

4.8

2.5

1.5

4.2

Myeloma

27

2.2

1.4

3.8

1.9

1.2

3.3

Asian Indian/Female

All Sites

821

67.4

62.2

73.1

58.7

54.2

63.6

Breast

178

11.2

9.4

13.5

9.9

8.3

11.8

Lung and bronchus

70

6.4

4.8

8.5

5.6

4.2

7.4

Colon and rectum

55

5.3

3.8

7.3

4.6

3.3

6.3

Ovary

66

5.0

3.7

6.8

4.3

3.2

5.9

Pancreas

37

3.5

2.4

5.2

3.1

2.1

4.5

Leukemia

48

3.5

2.4

5.1

3.0

2.1

4.4

Esophagus

28

2.8

1.7

4.4

2.4

1.5

3.7

Lymphoma—Non-Hodgkin

29

2.6

1.7

4.1

2.3

1.4

3.5

Liver and intrahepatic bile duct

29

2.6

1.7

4.0

2.3

1.5

3.5

Stomach

24

2.4

1.4

4.0

2.1

1.2

3.4

Brain and other nervous system

29

2.4

1.5

3.8

2.1

1.3

3.3

Cervix Uteri

28

2.2

1.4

3.6

1.9

1.2

3.1

Myeloma

25

2.1

1.3

3.4

1.8

1.1

2.9

Corpus and uterus, NOS

22

1.6

1.0

2.7

1.4

0.8

2.4

Gallbladder

20

1.5

0.9

2.6

1.3

0.8

2.3

Chinese/Male

All Sites

5,807

167.8

163.4

172.4

156.2

152.0

160.4

Lung and bronchus

1,603

47.0

44.7

49.5

43.9

41.7

46.2

Liver and intrahepatic bile duct

761

20.3

18.8

21.9

18.8

17.4

20.2

Colon and rectum

657

19.5

18.0

21.2

18.2

16.8

19.7

Stomach

404

11.7

10.5

12.9

10.9

9.8

12.1

Prostate

292

10.4

9.2

11.7

9.8

8.7

11.0

Pancreas

291

8.5

7.5

9.6

7.9

7.0

9.0

Leukemia

216

6.1

5.3

7.1

5.7

4.9

6.5

Lymphoma—Non-Hodgkin

205

6.0

5.2

6.9

5.6

4.8

6.4

Nasopharynx

192

4.5

3.9

5.2

4.1

3.5

4.7

Esophagus

134

3.8

3.1

4.5

3.5

2.9

4.2

Urinary bladder

109

3.6

3.0

4.4

3.4

2.8

4.2

Kidney and renal pelvis

102

2.9

2.3

3.5

2.7

2.2

3.3

Brain and other nervous system

94

2.5

2.0

3.1

2.3

1.8

2.8

Oral cavity (excl nasopharynx)

65

1.8

1.4

2.4

1.7

1.3

2.2

Myeloma

58

1.7

1.3

2.2

1.6

1.2

2.1

Larynx

33

0.9

0.6

1.3

0.9

0.6

1.2

Gallbladder

24

0.7

0.5

1.1

0.7

0.4

1.0

Melanoma of the skin

21

0.6

0.3

0.9

0.5

0.3

0.8

Chinese/Female

All Sites

4,537

107.7

104.5

110.9

99.6

96.6

102.5

Lung and bronchus

984

23.8

22.4

25.4

22.1

20.8

23.6

Colon and rectum

524

12.8

11.7

13.9

11.9

10.9

12.9

Breast

564

12.3

11.3

13.4

11.3

10.4

12.3

Liver and intrahepatic bile duct

308

7.4

6.5

8.2

6.8

6.1

7.6

Stomach

305

7.3

6.5

8.2

6.8

6.1

7.6

Pancreas

273

6.7

6.0

7.6

6.3

5.6

7.1

Ovary

229

5.2

4.6

6.0

4.8

4.2

5.5

Lymphoma—Non-Hodgkin

172

4.1

3.5

4.8

3.8

3.2

4.4

Leukemia

132

3.1

2.6

3.7

2.8

2.4

3.4

Cervix Uteri

93

2.2

1.8

2.7

2.0

1.6

2.5

Corpus and uterus, NOS

89

2.1

1.6

2.5

1.9

1.5

2.3

Brain and other nervous system

81

1.8

1.4

2.3

1.6

1.3

2.0

Kidney and renal pelvis

63

1.6

1.2

2.0

1.5

1.1

1.9

Nasopharynx

65

1.4

1.1

1.8

1.3

1.0

1.7

Myeloma

49

1.2

0.9

1.6

1.2

0.9

1.5

Esophagus

45

1.1

0.8

1.5

1.0

0.7

1.4

Urinary bladder

38

1.0

0.7

1.4

0.9

0.7

1.3

Oral cavity (excl nasopharynx)

34

0.8

0.6

1.1

0.8

0.5

1.1

Gallbladder

28

0.7

0.5

1.0

0.7

0.4

1.0

Thyroid

20

0.5

0.3

0.8

0.5

0.3

0.8

Filipino/Male

All Sites

3,890

155.6

150.6

160.8

142.3

137.7

147.0

Lung and bronchus

1,200

47.9

45.1

50.8

43.8

41.3

46.5

Prostate

377

17.8

16.1

19.8

16.6

14.9

18.3

Colon and rectum

411

16.1

14.6

17.8

14.8

13.3

16.3

Liver and intrahepatic bile duct

304

11.3

10.1

12.7

10.3

9.1

11.6

Lymphoma—Non-Hodgkin

226

9.1

7.9

10.4

8.3

7.2

9.5

Pancreas

171

7.0

6.0

8.2

6.5

5.5

7.5

Leukemia

155

5.7

4.8

6.7

5.1

4.3

6.0

Stomach

123

4.9

4.1

5.9

4.5

3.7

5.4

Myeloma

77

3.2

2.5

4.0

2.9

2.3

3.7

Kidney and renal pelvis

80

3.0

2.3

3.7

2.7

2.1

3.4

Brain and other nervous system

74

2.7

2.1

3.4

2.4

1.9

3.1

Esophagus

66

2.6

2.0

3.3

2.4

1.8

3.0

Urinary bladder

43

2.0

1.4

2.7

1.9

1.3

2.5

Oral cavity (excl nasopharynx)

46

1.8

1.3

2.5

1.7

1.2

2.3

Nasopharynx

45

1.5

1.1

2.1

1.4

1.0

1.9

Larynx

20

0.8

0.5

1.3

0.8

0.5

1.2

Thyroid

21

0.8

0.5

1.3

0.8

0.5

1.2

Gallbladder

18

0.7

0.4

1.2

0.7

0.4

1.1

Filipino/Female

All Sites

3,429

96.1

92.8

99.5

88.4

85.3

91.5

Breast

693

17.2

15.9

18.6

15.7

14.5

17.0

Lung and bronchus

592

17.2

15.8

18.7

15.9

14.6

17.3

Colon and rectum

314

9.0

8.0

10.1

8.3

7.3

9.3

Pancreas

207

6.3

5.4

7.2

5.8

5.0

6.7

Ovary

212

5.6

4.9

6.5

5.2

4.5

6.0

Lymphoma—Non-Hodgkin

143

4.4

3.7

5.3

4.1

3.4

4.9

Liver and intrahepatic bile duct

127

3.9

3.3

4.7

3.7

3.0

4.4

Stomach

101

3.2

2.6

3.9

2.9

2.4

3.6

Leukemia

112

3.1

2.5

3.8

2.8

2.3

3.4

Cervix Uteri

113

2.8

2.3

3.5

2.6

2.1

3.2

Corpus and uterus, NOS

106

2.8

2.3

3.4

2.5

2.1

3.1

Myeloma

80

2.4

1.9

3.0

2.2

1.8

2.8

Kidney and renal pelvis

52

1.4

1.1

1.9

1.3

1.0

1.8

Brain and other nervous system

50

1.4

1.0

1.9

1.2

0.9

1.7

Thyroid

41

1.2

0.8

1.6

1.1

0.8

1.5

Urinary bladder

20

0.7

0.4

1.1

0.6

0.4

1.0

Oral cavity (excl nasopharynx)

22

0.7

0.4

1.0

0.6

0.4

1.0

Gallbladder

21

0.7

0.4

1.0

0.6

0.4

1.0

Esophagus

21

0.6

0.4

1.0

0.6

0.3

0.9

Nasopharynx

17

0.5

0.3

0.8

0.4

0.2

0.7

Guamanian/Male

All Sites

60

147.0

106.5

201.8

111.8

81.6

152.4

Lung and bronchus

23

47.4

28.4

81.0

37.4

22.7

62.8

Guamanian/Female

All Sites

48

98.5

69.5

138.8

73.4

52.4

101.9

Native Hawaiian/Male c

All Sites

790

_

_

_

263.7

243.7

285.4

Lung and bronchus

257

_

_

_

87.7

76.4

100.7

Colon and rectum

81

_

_

_

26.9

20.8

34.9

Prostate

48

_

_

_

21.9

15.7

30.1

Stomach

44

_

_

_

14.1

9.9

20.2

Liver and intrahepatic bile duct

38

_

_

_

11.8

7.9

17.7

Pancreas

38

_

_

_

11.4

7.8

16.9

Leukemia

29

_

_

_

9.0

5.6

14.3

Esophagus

27

_

_

_

8.4

5.4

13.4

Lymphoma—Non-Hodgkin

26

_

_

_

8.0

4.9

13.2

Myeloma

18

_

_

_

5.2

3.0

9.5

Brain and other nervous system

16

_

_

_

3.9

2.1

7.8

Native Hawaiian/Female c

All Sites

738

_

_

_

198.9

184.4

214.4

Lung and bronchus

173

_

_

_

47.6

40.6

55.6

Breast

132

_

_

_

33.5

27.9

40.1

Pancreas

61

_

_

_

16.8

12.7

21.8

Colon and rectum

48

_

_

_

13.1

9.5

17.7

Stomach

36

_

_

_

10.3

7.1

14.6

Ovary

30

_

_

_

8.4

5.6

12.3

Corpus and uterus, NOS

26

_

_

_

6.7

4.3

10.2

Lymphoma—Non-Hodgkin

24

_

_

_

6.6

4.2

10.2

Liver and intrahepatic bile duct

22

_

_

_

6.4

3.9

10.0

Myeloma

18

_

_

_

5.2

3.1

8.5

Cervix Uteri

21

_

_

_

5.2

3.2

8.3

Leukemia

18

_

_

_

4.6

2.7

7.7

Japanese/Male

All Sites

3,327

173.7

167.7

179.9

162.7

157.1

168.4

Lung and bronchus

777

39.5

36.7

42.5

37.3

34.7

40.0

Colon and rectum

497

25.8

23.6

28.3

24.2

22.1

26.5

Stomach

315

16.6

14.8

18.7

15.6

13.9

17.5

Prostate

284

15.2

13.5

17.3

14.6

12.9

16.5

Pancreas

234

12.2

10.6

14.0

11.5

10.0

13.1

Liver and intrahepatic bile duct

170

9.1

7.8

10.8

8.5

7.2

9.9

Esophagus

142

7.8

6.6

9.3

7.2

6.1

8.5

Lymphoma—Non-Hodgkin

146

7.5

6.3

8.9

7.0

5.9

8.3

Leukemia

111

5.9

4.9

7.3

5.4

4.4

6.5

Kidney and renal pelvis

89

4.7

3.8

5.9

4.3

3.5

5.4

Urinary bladder

88

4.6

3.6

5.8

4.3

3.5

5.4

Brain and other nervous system

45

2.6

1.9

3.7

2.2

1.6

2.9

Oral cavity (excl nasopharynx)

37

1.9

1.4

2.9

1.8

1.3

2.5

Myeloma

30

1.4

1.0

2.2

1.4

0.9

2.0

Japanese/Female

All Sites

3,276

117.0

112.9

121.4

109.2

105.4

113.2

Lung and bronchus

585

19.7

18.1

21.5

18.6

17.1

20.3

Colon and rectum

421

15.3

13.8

17.0

14.4

13.0

15.9

Breast

385

15.1

13.6

16.9

13.9

12.5

15.4

Pancreas

314

10.6

9.4

12.1

10.1

9.0

11.3

Stomach

289

10.2

9.0

11.6

9.6

8.5

10.8

Liver and intrahepatic bile duct

196

6.5

5.6

7.7

6.1

5.2

7.0

Ovary

134

5.1

4.2

6.2

4.7

3.9

5.6

Lymphoma—Non-Hodgkin

143

5.0

4.2

6.1

4.7

4.0

5.6

Leukemia

104

4.0

3.2

5.1

3.6

3.0

4.4

Corpus and uterus, NOS

83

3.1

2.5

4.1

2.9

2.3

3.6

Cervix Uteri

40

1.7

1.2

2.5

1.5

1.1

2.1

Myeloma

47

1.6

1.2

2.3

1.5

1.1

2.0

Urinary bladder

42

1.4

1.0

2.2

1.4

1.0

1.9

Kidney and renal pelvis

37

1.3

0.9

2.1

1.2

0.9

1.8

Brain and other nervous system

28

1.2

0.8

2.0

1.0

0.7

1.5

Esophagus

33

1.1

0.8

1.8

1.1

0.7

1.6

Oral cavity (excl nasopharynx)

25

0.9

0.6

1.6

0.9

0.6

1.3

Gallbladder

23

0.8

0.5

1.4

0.7

0.5

1.1

Korean/Male

All Sites

1,762

196.5

186.2

207.4

188.6

178.6

199.0

Lung and bronchus

415

50.6

45.3

56.5

48.6

43.6

54.3

Stomach

302

31.5

27.5

36.0

30.2

26.4

34.6

Liver and intrahepatic bile duct

288

26.3

23.0

30.2

25.2

22.0

28.9

Colon and rectum

151

17.6

14.6

21.3

16.9

14.0

20.5

Pancreas

105

11.4

9.1

14.3

11.0

8.8

13.8

Prostate

43

6.8

4.7

9.5

6.5

4.6

9.2

Lymphoma—Non-Hodgkin

53

6.2

4.4

8.5

5.9

4.2

8.2

Leukemia

58

5.5

4.0

7.5

5.2

3.8

7.2

Urinary bladder

30

4.1

2.6

6.2

3.9

2.5

6.0

Esophagus

34

3.7

2.4

5.7

3.6

2.3

5.5

Gallbladder

20

3.1

1.8

5.2

3.0

1.7

5.0

Kidney and renal pelvis

28

3.0

1.9

4.7

2.9

1.9

4.5

Brain and other nervous system

27

2.0

1.3

3.4

1.9

1.2

3.3

Korean/Female

All Sites

1,561

108.2

102.6

114.1

104.2

98.8

109.9

Lung and bronchus

276

20.7

18.2

23.4

20.0

17.6

22.6

Stomach

211

14.5

12.5

16.8

14.0

12.1

16.2

Colon and rectum

171

12.1

10.3

14.2

11.7

9.9

13.7

Liver and intrahepatic bile duct

169

11.7

9.9

13.7

11.3

9.6

13.2

Breast

144

7.8

6.5

9.3

7.5

6.3

8.9

Pancreas

97

7.5

6.1

9.3

7.3

5.9

9.0

Ovary

71

4.5

3.5

5.8

4.3

3.3

5.6

Cervix Uteri

53

3.1

2.3

4.2

3.0

2.2

4.0

Lymphoma—Non-Hodgkin

39

2.9

2.1

4.1

2.8

2.0

4.0

Leukemia

43

2.6

1.8

3.6

2.5

1.7

3.5

Gallbladder

27

2.2

1.4

3.3

2.1

1.4

3.2

Corpus and uterus, NOS

26

1.7

1.1

2.6

1.6

1.0

2.5

Kidney and renal pelvis

20

1.7

1.0

2.6

1.6

1.0

2.5

Brain and other nervous system

23

1.5

0.9

2.3

1.4

0.9

2.2

Myeloma

18

1.4

0.8

2.3

1.4

0.8

2.2

Samoan/Male

All Sites

193

293.9

247.6

348.6

240.0

202.5

284.1

Lung and bronchus

54

74.0

53.6

102.9

61.2

44.4

84.6

Stomach

22

40.9

24.1

67.6

33.6

19.9

55.0

Prostate

14

36.2

18.9

64.4

29.2

15.3

51.5

Liver and intrahepatic bile duct

22

32.9

19.3

56.1

26.8

15.8

44.9

Colon and rectum

19

31.6

17.2

56.0

25.2

13.9

44.1

Samoan/Female

All Sites

172

209.3

176.5

248.2

170.7

144.0

202.1

Lung and bronchus

29

42.0

27.1

63.7

34.1

22.2

51.4

Breast

32

36.2

24.0

54.9

29.7

19.7

44.7

Vietnamese/Male

All Sites

1,398

159.9

149.9

170.7

150.6

141.1

160.7

Lung and bronchus

368

43.9

38.7

49.9

41.4

36.5

46.9

Liver and intrahepatic bile duct

335

33.8

29.6

38.8

31.9

27.9

36.6

Stomach

95

12.7

9.8

16.4

11.9

9.2

15.4

Pancreas

76

8.9

6.6

11.9

8.4

6.3

11.2

Colon and rectum

84

8.8

6.6

11.7

8.3

6.3

11.0

Leukemia

58

7.2

5.1

10.1

6.7

4.8

9.4

Prostate

30

6.7

4.3

10.0

6.2

4.0

9.4

Lymphoma—Non-Hodgkin

53

5.2

3.6

7.5

4.9

3.4

7.1

Oral cavity (excl nasopharynx)

30

3.6

2.2

5.9

3.4

2.0

5.5

Brain and other nervous system

31

2.9

1.7

4.9

2.7

1.6

4.6

Kidney and renal pelvis

18

2.6

1.3

4.8

2.4

1.3

4.5

Esophagus

19

2.6

1.4

4.7

2.4

1.3

4.4

Urinary bladder

18

2.0

1.1

3.8

1.9

1.1

3.6

Nasopharynx

22

1.7

1.0

3.3

1.6

0.9

3.1

Vietnamese/Female

All Sites

992

97.8

91.2

104.9

92.0

85.8

98.6

Lung and bronchus

181

20.2

17.1

23.7

19.0

16.1

22.3

Liver and intrahepatic bile duct

102

10.9

8.8

13.6

10.3

8.2

12.8

Breast

102

7.6

6.1

9.5

7.2

5.7

9.0

Colon and rectum

73

7.4

5.6

9.7

7.0

5.3

9.1

Stomach

72

7.0

5.3

9.2

6.6

5.0

8.7

Pancreas

62

6.2

4.7

8.3

5.9

4.4

7.8

Ovary

54

4.5

3.3

6.2

4.3

3.1

5.9

Cervix Uteri

52

4.4

3.2

6.1

4.2

3.0

5.8

Leukemia

51

4.2

3.0

5.8

3.9

2.8

5.4

Lymphoma–Non-Hodgkin

34

4.0

2.7

5.9

3.8

2.6

5.5

Myeloma

13

1.6

0.8

3.0

1.5

0.8

2.8

Brain and other nervous system

17

1.5

0.8

2.6

1.4

0.8

2.4

Corpus and uterus, NOS

17

1.4

0.8

2.6

1.4

0.8

2.4

Non − Hispanic White/Men d

All Sites

349,031

241.3

240.5

242.1

   

Lung and bronchus

106,623

72.2

71.8

72.7

   

Prostate

37,137

27.7

27.4

28.0

   

Colon and rectum

35,261

24.6

24.3

24.8

   

Pancreas

18,399

12.6

12.4

12.8

   

Lymphoma—Non-Hodgkin

15,368

10.6

10.5

10.8

   

Leukemia

15,119

10.6

10.4

10.8

   

Urinary bladder

11,682

8.4

8.2

8.6

   

Esophagus

11,536

7.7

7.6

7.9

   

Brain and other nervous system

9,477

6.3

6.2

6.4

   

Kidney and renal pelvis

9,135

6.2

6.1

6.3

   

Liver and intrahepatic bile duct

9,091

6.1

6.0

6.3

   

Stomach

8,395

5.8

5.7

5.9

   

Melanoma of the skin

6,998

4.7

4.6

4.8

   

Myeloma

6,454

4.5

4.4

4.6

   

Oral cavity a(excluding Nasopharynx)

5,605

3.7

3.6

3.8

   

Larynx

3,316

2.2

2.2

2.3

   

Lymphoma—Hodgkin

936

0.6

0.6

0.7

   

Gallbladder

683

0.5

0.4

0.5

   

Thyroid

673

0.5

0.4

0.5

   

Breast

504

0.3

0.3

0.4

   

Testis

475

0.3

0.3

0.4

   

Nasopharynx

383

0.3

0.2

0.3

   

Non − Hispanic White/Women d

All Sites

341,117

171.7

171.1

172.2

   

Lung and bronchus

87,084

44.5

44.2

44.8

   

Breast

53,534

27.8

27.5

28.0

   

Colon and rectum

36,430

17.3

17.1

17.5

   

Ovary

18,962

9.8

9.6

9.9

   

Pancreas

19,471

9.5

9.4

9.6

   

Lymphoma—Non-Hodgkin

14,024

6.8

6.7

7.0

   

Leukemia

12,132

6.0

5.9

6.1

   

Corpus and uterus, NOS

8,368

4.2

4.1

4.3

   

Brain and other nervous system

7,602

4.2

4.1

4.3

   

Myeloma

5,948

2.9

2.8

3.0

   

Stomach

5,930

2.8

2.8

2.9

   

Kidney and renal pelvis

5,611

2.8

2.7

2.9

   

Liver and intrahepatic bile duct

5,546

2.7

2.7

2.8

   

Urinary bladder

5,228

2.4

2.3

2.5

   

Cervix Uteri

4,206

2.4

2.3

2.5

   

Melanoma of the skin

4,075

2.2

2.1

2.2

   

Corpus Uteri

3,822

1.9

1.9

2.0

   

Esophagus

3,766

1.8

1.8

1.9

   

Oral cavity a(excluding Nasopharynx)

3,142

1.6

1.5

1.6

   

Gallbladder

1,675

0.8

0.8

0.9

   

Larynx

992

0.5

0.5

0.6

   

Lymphoma—Hodgkin

800

0.5

0.4

0.5

   

Thyroid

917

0.5

0.4

0.5

   

Nasopharynx

245

0.1

0.1

0.1

   

aRates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following States: CA, HI, IL, NJ, NY, TX, and WA

bCancers are sorted in descending order of the rate within each race/ethnic and sex group

cRates for Native Hawaiians are calculated using only the one or more race/ethnicities population denominator (See Materials and methods)

dRates for Non-Hispanic Whites are calculated using the bridged single-race population denominator (See Materials and methods)

Copyright information

© The Author(s) 2007